Actively Recruiting
LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)
Led by University Hospital, Angers · Updated on 2025-07-02
320
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Angers
Lead Sponsor
N
National Cancer Institute, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Childhood cancer survivors represent a high-risk population that requires risk-based follow-up. Follow-up recommendations have been harmonized. Education and information practices regarding follow-up recommendations should be personalized, to ensure understanding by all survivors, including those with neurocognitive disorders. Individualized follow-up is necessary to detect complications that may increase morbidity and decrease quality of life, or even increase the risk of early mortality. In France, the LOG-AFTER software was developed in 2017 by university hospital of Angers and Epiconcept (approved health data host). The main differences with the European procedure concern radiotherapy information, the link with the General practitioner (GP), and the possible addition of information and/or access to therapeutic education in a video format. Indeed, there is the possibility of creating an GP account allowing to receive notifications concerning the follow-up of his patient to be scheduled, to have access to his file summary and his personalized follow-up plan, various information and blank prescription models. LOG-I is a study of the impact of the LOG-AFTER software for the "patient/GP" couple on adherence to follow-up recommendations. LOG-I is interested in all former patients with at least 3 recommendations in their personalized follow-up plan, taking into account the specific population of patients cured of a brain tumor.
CONDITIONS
Official Title
LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Previously treated for cancer or malignant hematological disease before age 25
- No active disease or stable disease without treatment for 5 years or more
- Own a computer, smartphone, or tablet with internet access
- Signed informed consent (patient or parent/guardian for minors)
- Have at least 3 recommended screenings in personalized follow-up plan
- No prior access or connection to LOG-AFTER within the past 24 months
You will not qualify if you...
- Relapse or second cancer with less than 5 years since treatment
- Not covered by health insurance
- Under legal protection, deprived of liberty by judicial or administrative decision, or under forced psychiatric care
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital of Angers
Angers, Maine Et Loire, France, 49933
Actively Recruiting
Research Team
S
Sandra MERZEAU
CONTACT
P
Pascal VEILLON
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here